Introgen Therapeutics, Inc. (NASDAQ: INGN) reported Q1 EPS of $0.05, $0.01 better than the analyst estimate of $0.04. Revenue for the quarter rose 50.1% to $23.6 million versus the consensus estimate of $20.7 million.

Introgen Therapeutics, Inc. sees FY2014 revenue up 22-27% to $92-96 million, versus the consensus of $91.7 million and versus its previous guidance of $90-$34 million. Adjusted EBITDA is projected to be in the range of $18.0 to $19.5 million which is updated from the previous range of $17.5 to $19.0 million. Net income is projected to be in the range of $4.0 to $5.0 million, which is unchanged from previous guidance

"We are pleased with our unseasonably strong first quarter performance, which included the highest quarterly revenue we have ever recorded, and we are well positioned to deliver on our 2014 corporate objectives," said President and Chief Executive Officer, Raymond Huggenberger. "As we continue to execute on our strategic initiatives, we remain focused on increasing awareness of our product offerings and delivering meaningful innovative oxygen products to more patients globally.

For earnings history and earnings-related data on Introgen Therapeutics, Inc. (INGN) click here.